메뉴 건너뛰기




Volumn 74, Issue 11, 2015, Pages 2006-2015

Efficacy and safety of Atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE):52-week data (April-SLE randomised trial)

Author keywords

[No Author keywords available]

Indexed keywords

ATACICEPT; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN; PLACEBO; ANTINUCLEAR ANTIBODY; ANTIRHEUMATIC AGENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; HYBRID PROTEIN; TACI RECEPTOR-IGG FC FRAGMENT FUSION PROTEIN;

EID: 84945242898     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-205067     Document Type: Article
Times cited : (247)

References (21)
  • 2
    • 80155204725 scopus 로고    scopus 로고
    • Assessment of lupus nephritis cohort over a 30-year period
    • Croca S, Rodrigues T, Isenberg DA. Assessment of lupus nephritis cohort over a 30-year period. Rheumatology 2011;50:1424-30.
    • (2011) Rheumatology , vol.50 , pp. 1424-1430
    • Croca, S.1    Rodrigues, T.2    Isenberg, D.A.3
  • 3
    • 84945222214 scopus 로고    scopus 로고
    • B cells in systemic lupus erythematosus
    • Wallace DJ, Hahn BH. eds, 7th edn. Philadelphia, PA: Lippincott, Williams & Wilkins
    • Stamatis-Nick C, Tsokos GC. B cells in systemic lupus erythematosus. In: Wallace DJ, Hahn BH. eds. Dubois Lupus Erythematosus. 7th edn. Philadelphia, PA: Lippincott, Williams & Wilkins, 2007:176-90.
    • (2007) Dubois Lupus Erythematosus , pp. 176-190
    • Stamatis-Nick, C.1    Tsokos, G.C.2
  • 4
    • 84871838942 scopus 로고    scopus 로고
    • B cell elimination in systemic lupus erythematosus
    • Furtado J, Isenberg DA. B cell elimination in systemic lupus erythematosus. Clin Immunol 2013;146:90-103.
    • (2013) Clin Immunol , vol.146 , pp. 90-103
    • Furtado, J.1    Isenberg, D.A.2
  • 5
    • 74849131972 scopus 로고    scopus 로고
    • Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial
    • Merrill JT, Neuelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62:222-33.
    • (2010) Arthritis Rheum , vol.62 , pp. 222-233
    • Merrill, J.T.1    Neuelt, C.M.2    Wallace, D.J.3
  • 6
    • 84866184129 scopus 로고    scopus 로고
    • Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study
    • Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64:1215-26.
    • (2012) Arthritis Rheum , vol.64 , pp. 1215-1226
    • Rovin, B.H.1    Furie, R.2    Latinis, K.3
  • 7
    • 79952070370 scopus 로고    scopus 로고
    • Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomized placebo-controlled, phase 3 trial
    • Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomized placebo-controlled, phase 3 trial. Lancet 2011;377:721-31.
    • (2011) Lancet , vol.377 , pp. 721-731
    • Navarra, S.V.1    Guzmán, R.M.2    Gallacher, A.E.3
  • 8
    • 82455198794 scopus 로고    scopus 로고
    • A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
    • Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-30.
    • (2011) Arthritis Rheum , vol.63 , pp. 3918-3930
    • Furie, R.1    Petri, M.2    Zamani, O.3
  • 9
    • 37149032474 scopus 로고    scopus 로고
    • Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicentre, phase 1b, double-blind, placebo-controlled, dose-escalating trial
    • Dall'Era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicentre, phase 1b, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007;56:4142-50.
    • (2007) Arthritis Rheum , vol.56 , pp. 4142-4150
    • Dall'Era, M.1    Chakravarty, E.2    Wallace, D.3
  • 10
    • 0037108490 scopus 로고    scopus 로고
    • BLyS and April form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases
    • Roschke V, Sosnovtseva S, Ward CD, et al. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 2002;169:4314-21.
    • (2002) J Immunol , vol.169 , pp. 4314-4321
    • Roschke, V.1    Sosnovtseva, S.2    Ward, C.D.3
  • 11
    • 0347285357 scopus 로고    scopus 로고
    • BCMA is essential for the survival of long-lived bone marrow plasma cells
    • O'Connor BP, Raman VS, Erickson LD, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004;199:91-8.
    • (2004) J Exp Med , vol.199 , pp. 91-98
    • O'Connor, B.P.1    Raman, V.S.2    Erickson, L.D.3
  • 12
    • 0027325557 scopus 로고
    • The BILAG index: A reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus
    • Hay EM, Bacon P, Gordon C, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. QJ Med 1993;86:447-58.
    • (1993) QJ Med , vol.86 , pp. 447-458
    • Hay, E.M.1    Bacon, P.2    Gordon, C.3
  • 13
    • 17744370325 scopus 로고    scopus 로고
    • From BILAG to BLiPS-disease activity assessment in lupus past, present and future
    • Isenberg DA, Gordon C; on behalf of the BILAG group. From BILAG to BLiPS-disease activity assessment in lupus past, present and future. Lupus 2000;9:651-4.
    • (2000) Lupus , vol.9 , pp. 651-654
    • Isenberg, D.A.1    Gordon, C.2
  • 14
    • 0020436689 scopus 로고
    • The 1982 revised criteria for the classification of systemic lupus erythematosus
    • Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-2.
    • (1982) Arthritis Rheum , vol.25 , pp. 1271-1272
    • Tan, E.M.1    Cohen, A.S.2    Fries, J.F.3
  • 15
    • 0031229830 scopus 로고    scopus 로고
    • Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus (letter)
    • Hochberg MC. Updating the American College of Rheumatology Revised Criteria for the Classification of Systemic Lupus Erythematosus (letter). Arthritis Rheum 1997;40:1725.
    • (1997) Arthritis Rheum , vol.40 , pp. 1725
    • Hochberg, M.C.1
  • 16
    • 34447320202 scopus 로고    scopus 로고
    • Fifty years of anti-dsDNA antibodies-are we approaching journey's end?
    • Isenberg DA, Manson JJ, Ehrenstein MR, et al. Fifty years of anti-dsDNA antibodies-are we approaching journey's end? Rheumatology 2007;46:1052-6.
    • (2007) Rheumatology , vol.46 , pp. 1052-1056
    • Isenberg, D.A.1    Manson, J.J.2    Ehrenstein, M.R.3
  • 18
    • 84856795563 scopus 로고    scopus 로고
    • Atacicept in combination with MMF and corticosteroids in lupus nephritis: Results of a prematurely terminated trial
    • Ginzler EM, Wax S, Rajeswaran A, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther 2012;14:R33.
    • (2012) Arthritis Res Ther , vol.14 , pp. R33
    • Ginzler, E.M.1    Wax, S.2    Rajeswaran, A.3
  • 19
    • 79959856423 scopus 로고    scopus 로고
    • Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase II, randomized, placebo-controlled trial
    • Van Vollenhoven RF, Kinnman N, Vincent E, et al. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. Arthritis Rheum 2011;63:1782-92.
    • (2011) Arthritis Rheum , vol.63 , pp. 1782-1792
    • Van Vollenhoven, R.F.1    Kinnman, N.2    Vincent, E.3
  • 20
    • 74849131972 scopus 로고    scopus 로고
    • Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial
    • Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62:222-33.
    • (2010) Arthritis Rheum , vol.62 , pp. 222-233
    • Merrill, J.T.1    Neuwelt, C.M.2    Wallace, D.J.3
  • 21
    • 0242524630 scopus 로고    scopus 로고
    • Definition and treatment of lupus flare measured by the BILAG index
    • Gordon C, Sutcliffe N, Skan J, et al. Definition and treatment of lupus flare measured by the BILAG index. Rheumatology 2003;42:1372-9.
    • (2003) Rheumatology , vol.42 , pp. 1372-1379
    • Gordon, C.1    Sutcliffe, N.2    Skan, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.